Skip to main content

Proposed benefits of albumin from the ALBIOS trial: a dose of insane belief

Abstract

No abstract.

We read with interest the editorial by Flannery and colleagues [1], who proposed `a dose of healthy skepticism’ toward the findings of our Albumin Italian Outcome Sepsis (ALBIOS) trial [2]. Although we feel uncertain about where such `health’ may come from, we consider a few extra words necessary. First, the rationale of the subgroup analysis of 90-day mortality on septic shock was based on the Kaplan-Meier estimates for 90-day survivals of the entire study population, which tended to separate between groups from day 30. Although this observation was unexpected, it indicates the potential beneficial effects of ancillary functions of albumin, besides its oncotic property [3]-[5]. When patients with shock as defined in a broader view (with cardiovascular Sequential Organ Failure Assessment score of 1, 3, or 4; n = 1,303) were considered, the beneficial effect of albumin on 90-day survival persisted (relative risk (RR) 0.88, 95% confidence interval (CI) 0.78 to 0.99, P = 0.03) even after adjustment for clinically relevant variables (RR 0.88, 95% CI 0.78 to 1.00, P = 0.049). Second, we agree with the authors on the potential biases of an open-label study. Nonetheless, we believe that the shorter time to suspension of vasopressors observed in the albumin as compared with the crystalloid group is a solid finding, as supported by a higher or equal mean arterial pressure over the study observed in the former as compared with the latter group [2]. In conclusion, the available data suggest not only that albumin may be a safe alternative to crystalloids in patients with severe sepsis but that it may be beneficial in those with shock [6]. Further studies are warranted to confirm this hypothesis.

Abbreviations

Cl:

Confidence interval

RR:

Relative risk

References

  1. 1.

    Flannery AH, Kane SP, Coz-Yataco AO: A word of caution regarding proposed benefits of albumin from ALBIOS: a dose of healthy skepticism. Crit Care. 2014, 18: 509-10.1186/s13054-014-0509-x.

    PubMed Central  Article  Google Scholar 

  2. 2.

    Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, Fanizza C, Caspani L, Faenza S, Grasselli G, Iapichino G, Antonelli M, Parrini V, Fiore G, Latini R, Gattinoni L: Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014, 370: 1412-1421. 10.1056/NEJMoa1305727.

    CAS  Article  Google Scholar 

  3. 3.

    Quinlan GJ, Martin GS, Evans TW: Albumin: biochemical properties and therapeutic potential. Hepatology. 2005, 41: 1211-1219. 10.1002/hep.20720.

    CAS  Article  Google Scholar 

  4. 4.

    Caironi P, Gattinoni L: The clinical use of albumin: the point of view of a specialist in intensive care. Blood Transfus. 2009, 7: 259-267.

    PubMed Central  Google Scholar 

  5. 5.

    O’Brien AJ, Fullerton JN, Massey KA, Auld G, Sewell G, James S, Newson J, Karra E, Winstanley A, Alazawi W, Garcia-Martinez R, Cordoba J, Nicolaou A, Gilroy DW: Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat Med. 2014, 20: 518-523. 10.1038/nm.3516.

    Article  Google Scholar 

  6. 6.

    Caironi P, Tognoni G, Gattinoni L: Albumin replacement in severe sepsis or septic shock. N Engl J Med. 2014, 371: 84-10.1056/NEJMc1405198.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Pietro Caironi.

Additional information

Competing interests

PC has received lecture honoraria from CSL Behring (King of Prussia, PA, USA) and Grifols (Barcelona, Spain). LG has received lecture honoraria from CSL Behring, Grifols, Kedrion (Barga, Italy), and Baxter (Deerfield, IL, USA).

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Caironi, P., Gattinoni, L. Proposed benefits of albumin from the ALBIOS trial: a dose of insane belief. Crit Care 18, 510 (2014). https://doi.org/10.1186/s13054-014-0510-4

Download citation

Keywords

  • Albumin
  • Septic Shock
  • Severe Sepsis
  • Sequential Organ Failure Assessment
  • Sequential Organ Failure Assessment Score